288 related articles for article (PubMed ID: 27012121)
1. [Thalidomide induced peripheral neuropathy in multiple myeloma patients].
Banach M; Jurczyszyn A; Skotnicki A
Przegl Lek; 2015; 72(11):629-35. PubMed ID: 27012121
[TBL] [Abstract][Full Text] [Related]
2. Clinical and electrophysiological evaluation of patients with thalidomide-induced neuropathy.
Kocer B; Sucak G; Kuruoglu R; Aki Z; Haznedar R; Erdogmus NI
Acta Neurol Belg; 2009 Jun; 109(2):120-6. PubMed ID: 19681443
[TBL] [Abstract][Full Text] [Related]
3. Neuropathy in multiple myeloma treated with thalidomide: a prospective study.
Plasmati R; Pastorelli F; Cavo M; Petracci E; Zamagni E; Tosi P; Cangini D; Tacchetti P; Salvi F; Bartolomei I; Michelucci R; Tassinari CA
Neurology; 2007 Aug; 69(6):573-81. PubMed ID: 17679676
[TBL] [Abstract][Full Text] [Related]
4. Treatment of multiple myeloma: thalidomide-, bortezomib-, and lenalidomide-induced peripheral neuropathy.
Koeppen S
Oncol Res Treat; 2014; 37(9):506-13. PubMed ID: 25231692
[TBL] [Abstract][Full Text] [Related]
5. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues.
Delforge M; Bladé J; Dimopoulos MA; Facon T; Kropff M; Ludwig H; Palumbo A; Van Damme P; San-Miguel JF; Sonneveld P
Lancet Oncol; 2010 Nov; 11(11):1086-95. PubMed ID: 20932799
[TBL] [Abstract][Full Text] [Related]
6. Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations.
Mohty B; El-Cheikh J; Yakoub-Agha I; Moreau P; Harousseau JL; Mohty M
Haematologica; 2010 Feb; 95(2):311-9. PubMed ID: 20139393
[TBL] [Abstract][Full Text] [Related]
7. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring.
Mileshkin L; Stark R; Day B; Seymour JF; Zeldis JB; Prince HM
J Clin Oncol; 2006 Sep; 24(27):4507-14. PubMed ID: 16940275
[TBL] [Abstract][Full Text] [Related]
8. Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathy.
Offidani M; Corvatta L; Marconi M; Malerba L; Mele A; Olivieri A; Brunori M; Catarini M; Candela M; Capelli D; Montanari M; Rupoli S; Leoni P
Eur J Haematol; 2004 Jun; 72(6):403-9. PubMed ID: 15128418
[TBL] [Abstract][Full Text] [Related]
9. Pharmacovigilance of patients with multiple myeloma being treated with bortezomib and/or thalidomide.
Castro TB; Hallack Neto AE; Atalla A; Ribeiro LC
Braz J Med Biol Res; 2016; 49(6):e5128. PubMed ID: 27254660
[TBL] [Abstract][Full Text] [Related]
10. Low serum vitamin D occurs commonly among multiple myeloma patients treated with bortezomib and/or thalidomide and is associated with severe neuropathy.
Wang J; Udd KA; Vidisheva A; Swift RA; Spektor TM; Bravin E; Ibrahim E; Treisman J; Masri M; Berenson JR
Support Care Cancer; 2016 Jul; 24(7):3105-10. PubMed ID: 26902977
[TBL] [Abstract][Full Text] [Related]
11. The magnitude of neurotoxicity in patients with multiple myeloma and the impact of dose modifications: results from the population-based PROFILES registry.
Beijers AJ; Oerlemans S; Mols F; Eurelings M; Minnema MC; Vreugdenhil A; van de Poll-Franse LV
Ann Hematol; 2017 Apr; 96(4):653-663. PubMed ID: 28116479
[TBL] [Abstract][Full Text] [Related]
12. Pathophysiology of drug-induce peripheral neuropathy in patients with multiple myeloma.
Luczkowska K; Litwinska Z; Paczkowska E; Machalinski B
J Physiol Pharmacol; 2018 Apr; 69(2):. PubMed ID: 29920472
[TBL] [Abstract][Full Text] [Related]
13. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
Badros A; Goloubeva O; Dalal JS; Can I; Thompson J; Rapoport AP; Heyman M; Akpek G; Fenton RG
Cancer; 2007 Sep; 110(5):1042-9. PubMed ID: 17654660
[TBL] [Abstract][Full Text] [Related]
14. [Thalidomide in the treatment of refractory multiple myeloma: a Dutch study of 72 patients: an antitumor effect in 45%].
Wu KL; Schaafsma MR; Lokhorst HM; Wijermans PW; van der Holt B; Sonneveld P
Ned Tijdschr Geneeskd; 2002 Aug; 146(31):1445-8. PubMed ID: 12190011
[TBL] [Abstract][Full Text] [Related]
15. Thalidomide neurotoxicity.
Clemmensen OJ; Olsen PZ; Andersen KE
Arch Dermatol; 1984 Mar; 120(3):338-41. PubMed ID: 6703734
[TBL] [Abstract][Full Text] [Related]
16. [Experience of using thalidomide in the treatment of patients with multiple myeloma].
Novosad OI; Kriachok IA; Kadnikova TV; Tytorenko IB; Sychova TV; Kostiukova NI
Lik Sprava; 2010; (3-4):79-86. PubMed ID: 21265124
[TBL] [Abstract][Full Text] [Related]
17. Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma.
Tosi P; Zamagni E; Cellini C; Plasmati R; Cangini D; Tacchetti P; Perrone G; Pastorelli F; Tura S; Baccarani M; Cavo M
Eur J Haematol; 2005 Mar; 74(3):212-6. PubMed ID: 15693790
[TBL] [Abstract][Full Text] [Related]
18. Multiple myeloma.
Crawford CL
N Engl J Med; 2005 Feb; 352(8):840-1; author reply 840-1. PubMed ID: 15736295
[No Abstract] [Full Text] [Related]
19. Features and risk factors of peripheral neuropathy during treatment with bortezomib for advanced multiple myeloma.
El-Cheikh J; Stoppa AM; Bouabdallah R; de Lavallade H; Coso D; de Collela JM; Auran-Schleinitz T; Gastaut JA; Blaise D; Mohty M
Clin Lymphoma Myeloma; 2008 Jun; 8(3):146-52. PubMed ID: 18650177
[TBL] [Abstract][Full Text] [Related]
20. Management of treatment-related adverse events in patients with multiple myeloma.
Mateos MV
Cancer Treat Rev; 2010 May; 36 Suppl 2():S24-32. PubMed ID: 20472185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]